Pfizer (PFE) Sees Approval of MRNA Flu Vaccine in 2024 - Bloomberg, Citing Presentation
Tweet
Share
E-mail
Get Alerts PFE Hot Sheet
Price: $24.37 +0.33%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 7.1%
Revenue Growth %: -1.8%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 7.1%
Revenue Growth %: -1.8%
Join SI Premium – FREE
Pfizer (NYSE: PFE) Sees Approval of MRNA Flu Vaccine in 2024 - Bloomberg, Citing Presentation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA extends review of Praxis drug for rare epilepsy to December 2026
- FDA selects 7 companies for domestic drug manufacturing pilot
- Santacruz Silver reports employee fatality at Bolivia's Reserva mine
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
